六味通脉胶囊对动脉硬化闭塞症患者T细胞亚群及白细胞介素-6、肿瘤坏死因子-α的影响

Influence of Liuweitongmai capsule on T cell subgroup, Interleukin-6 and tumor necrosis factor-α in patients with arteriosclerotic occlusive disease

目的研究六味通脉胶囊对动脉硬化闭塞症(ASO)患者外周血白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)含量变化及T细胞亚群的影响,并进一步探讨该复方中药抗ASO的作用机制。方法将93例符合入选标准的ASO患者,采用双盲双模拟研究方法,随机分为治疗组和对照组,从T细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)I、L-6、TNF-α含量变化等方面进行前瞻性对比治疗研究。结果ASO患者存在免疫功能的低下,血液IL-6、TNF-α含量明显升高,与健康人比较有显著性差异(P<0.05或0.01)。经3个疗程的治疗后,2组患者的各观察指标均有不同程度的改善,与治疗前比较有显著性差异(P<0.05或0.01);治疗后治疗组与对照组比较,有显著性差异(P<0.05或0.01)。结论六味通脉胶囊能明显提高免疫功能,降低血液IL-6、TNF-α的含量。六味通脉胶囊对ASO患者的预后影响与提高免疫功能及降低血液IL-6、TNF-α的含量有关。

Objective It is to study the content changes of Liuweitongmai capsule on Interleukin- 6 （IL- 6） and tumor necrosis factor - α （TNF - α） of peripheral blood in patients with arteriosclerotic occlusive disease （ASO） and the influence on T cell subgroup, and to further discuss the action mechanism of anti-ASO of the compound traditional Chinese drug. Methods 93 ASO patients who were consistent with selected standard were randomly divided into treatment group and control group with double-blind and double-simulation investigative method. The prospective contrast therapeutic study was done from the content changes of T cell subgroup （CD3^＋ , CD4^ ＋ , CD8^＋ , CD4^＋/CD8^＋ ）, IL- 6, TNF- α and so on. Results The immune function of ASO patients was low and the blood contents of IL - 6 and TNF - α were obviously heightened, which had significant difference compared with that in health persons （P〈 0.05 or 0.01）. All the observation indexes in the two groups had improved with different degree after three courses of treatment, which had significant difference compared with that before treatment （P 〈 0.05 or 0.01 ）. There was significant difference on all the observation indexes after treatment between treatment group and control group （ P〈 0.05 or 0.01 ）. Conclusion Liuweitongmai capsule can obviously heighten immune function and lower the blood contents of IL - 6 and TNF -α. The influence of Liuweitongmai capsule on the prognosis of AS（3 patients is relative to heightening immune function and lowering the blood contents of IL - 6 and TNF- α.